E2 Disruption & Cancer

Mapping the integration patterns, E2 gene disruption frequencies, and molecular consequences across HPV-positive tumors.

6
Cancer Types
693
Samples Analyzed
95.8%
Peak Disruption (HPV18)
6.1x
Max E6/E7 Fold Change

E2 Protein Structure & Breakpoints

The E2 protein consists of an N-terminal Transactivation Domain (TAD), a flexible hinge region, and a C-terminal DNA Binding Domain (DBD). Breakpoints during viral integration frequently occur within the vulnerable hinge region.

TAD (1-200)
Hinge (200-280)
DBD (280-365)
⚡
Common integration breakpoint within the E2 hinge region.

Integration Data Explorer

Cancer Type ↕ Genotype ↕ Samples ↕ E2 Disrupted ↕ E6/E7 Change ↕ Common Breakpoint Source (PMID)

Frequently Asked Questions

Why is E2 disruption important in HPV-positive cancers? +
The E2 protein typically represses the transcription of the viral oncogenes E6 and E7. When HPV integrates into the host genome, the E2 gene is frequently disrupted or deleted. This loss of E2 repression leads to the uncontrolled overexpression of E6 and E7, driving cellular transformation and cancer progression.
Which region of the E2 gene is most commonly disrupted? +
The E2 hinge region (amino acids 200-250) is highly susceptible to breaks during integration. In many HPV16 cases, integration breakpoints cluster heavily in this domain.
Does E2 disruption occur in all HPV-positive cancers? +
No. While it is extremely common (e.g., ~78.5% in HPV16+ cervical cancer), some tumors maintain intact, episomal HPV genomes, or have integrated HPV where the E2 gene remains intact but is silenced via methylation.
How does E2 disruption affect patient prognosis? +
In cervical cancer, E2 disruption often correlates with a more aggressive phenotype and poorer patient survival outcomes due to the stable overexpression of E6 and E7 oncogenes.
Are there differences in E2 disruption rates between cancer types? +
Yes. Our compiled data shows that cervical cancers exhibit very high E2 disruption rates (78.5% for HPV16, 95.8% for HPV18), whereas HPV-positive oropharyngeal and head/neck cancers tend to have lower disruption rates (41-45%), often maintaining episomal viral DNA.

Methodology & Sources

Data was compiled from a literature review of peer-reviewed studies detailing HPV integration across various cancer types. Sample sizes, E2 disruption rates, breakpoint regions, and E6/E7 expression levels were extracted and standardized.


Sources (PMIDs):

© 2026 HPV Research · A GAB Ventures property
This content is for educational and research purposes only. It is not medical advice. Consult a healthcare professional for any medical decisions.